FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
FDA: Knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...
FDA Says Shortage of Eli Lilly’s Zepbound is Over, But Gives Compounders a Grace Period
JACKSON, Miss. (WJTV) – When President Joe Biden commuted the prison terms of hundreds of so-called “non-violent” offenders ...
The FDA says the Zepbound shortage is over. That's rattling the weight loss industry
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide—the active ingredient in Eli ...
The Pantagraph1d
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter. The drugmaker plans to start construction of the expansion next year.
Sleep expert shares tips to wake up refreshed during the holidays
From using jet lag apps to soundproofing your room, Dr. Shelby Harris, psychologist and director of sleep at Sleepopolis, ...
Winnipeg Free Press14d
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Seeking Alpha14d
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the country's National Institute for Health and Care Excellence ("NICE") said ...
HealthLeaders Media14d
Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in first head-to-head study
In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy. People taking Zepbound lost 20.2% of ...